CUMBERLAND PHARMACEUTICALS INC Fair Value Disclosure
| December 31, 2020 | December 31, 2019 | |||||||||||||||||||||||||||||||||||||
| Level 1 | Level 2 | Total | Level 1 | Level 2 | Total | |||||||||||||||||||||||||||||||||
| Commercial Paper | — | — | — | — | $ | 2,119,607 | $ | 2,119,607 | ||||||||||||||||||||||||||||||
| Total fair value of marketable securities | $ | — | $ | — | $ | — | $ | — | $ | 2,119,607 | $ | 2,119,607 | ||||||||||||||||||||||||||
Want the next CUMBERLAND PHARMACEUTICALS INC fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CUMBERLAND PHARMACEUTICALS INC's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2020 | Mar 12, 2021 | Showing above |
| 2019 | Mar 20, 2020 | |
| 2018 | Mar 12, 2019 | |
| 2017 | Mar 9, 2018 | |
| 2016 | Mar 13, 2017 | |
| 2015 | Mar 14, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.